Rokit Healthcare Co., Ltd. has received the '2025 Korea Small and Medium Enterprise Award' in the bio category. Since its establishment in 2012, the company has led innovation in the bio-medical industry by developing the world's first hyper-personalized artificial organ regeneration platform that integrates AI, 3D bioprinting, and bio-ink technologies.

In 2023, the company entered the global market by obtaining CE MDR and FDA certifications with its skin regeneration platform and completed the world's first AI hyper-personalized organ regeneration platform, gaining recognition for its technological capabilities. After entering the KOSDAQ market through a technology special listing in 2024, the company achieved its first quarterly operating profit surplus, demonstrating both profitability and growth potential as a technology company.

Currently, with its customized skin regeneration technology for diabetic foot, the company has completed U.S. patent registration, clinical success in Japan, and technology approval in Italy, and is expanding its global market by signing sales contracts with 46 countries. CEO Yoo Seok-hwan stated, "We will open a new paradigm in the treatment of intractable diseases such as diabetic foot, skin cancer, renal failure, and heart failure through AI organ regeneration."

Popular News